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Th17 and Th9 cells have been demonstrated to possess immune regulatory functions in malignant pleural effusion (MPE). 
However, whether IL-17 can affect differentiation and function of Th9 cells in MPE remains unknown. The objective of the 
present study was to explore the impact of IL-17 on the in vivo differentiation of Th9 cells in relation to Th2 cells in a murine 
model of MPE, and to explore whether IL-17 inhibits MPE formation via IL-9‒dependent mechanism. It was found that Th9 
and Th2 cells were decreased in MPE from IL-17–/– mice as compared with wild type mice. IL-17 deficiency inhibited Th9 and 
Th2 cell differentiation via suppressing transcription factors IRF4 and GATA-3, respectively. IL-17 deficiency enhanced MPE 
formation by promoting angiogenesis and proliferation of pleural tumors, and thus accelerated the death of mice bearing MPE. 
The in vivo administration of anti-IL-9 neutralizing mAb accelerated the death of WT mice; whereas administration of exoge-
nous IL-9 improved the survival of IL-17–/– mice. Our data provide the first definitive evidence that IL-17 promotes the differ-
entiation of Th9 and Th2 cells in MPE. Our findings also demonstrate that IL-17 inhibits the formation of MPE and improves 
the survival of mice bearing MPE via an IL-9–dependent mechanism. 
malignant pleural effusion, interleukin 17, Th9 cells 
 
Citation:  Lu, Y., Lin, H., Zhai, K., Wang, X., Zhou, Q., and Shi, H. (2016). Interleukin-17 inhibits development of malignant pleural effusion via interleu-





IL-9, a member of the IL-2 cytokine family, is produced by 
naïve CD4+ T lymphocytes in response to IL-4 and TGF- 
(Dardalhon et al., 2008; Veldhoen et al., 2008). IL-9 has 
been suggested to possess a functional role in some malig-
nant lymphomas, such as Hodgkin’s disease and large-cell 
anaplastic lymphoma (Fischer et al., 2003; Merz et al., 
1991). It has been demonstrated that IL-9 plays a role dur-
ing tumor genesis because dysregulated IL-9 response re-
sults in autonomous cell growth and malignant transfor-
mation of lymphoid cells associated with constitutive acti-
vation of the Jak/STAT pathway (Knoops and Renauld, 
2004). 
Malignant pleural effusion (MPE) is a frequent and clin-
ically significant systemic manifestation of various malig-
nancies that adversely affects patient survival and quality of 
life (Kastelik, 2013; Roberts et al., 2010). It has been well 
documented that CD4+ T cell dominance occurs in MPE. 
Naïve CD4+ T cells become activated and differentiate into 
effector T helper (Th) cell subgroups, depending on the an-
tigens and cytokine microenvironment they encounter. Our 
previous studies have demonstrated that several subgroups 
of CD4+ T cells, such as regulatory T cells (Tregs) (Chen et 
al., 2005), IL-17–producing CD4+ T cells (Th17 cells) (Ye 
et al., 2010), IL-22–producing CD4+ T cells (Th22 cells) 
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(Ye et al., 2012a), and IL-9–producing CD4+ T cells (Th9 
cells) (Ye et al., 2012b), play important immune regulatory 
roles in the pathogenesis of human MPE. 
The relationship between Th9 and Th17 cells is of par-
ticular interest, and their immune regulation is often linked 
to proinflammatory and malignant processes. IL-9 can be 
produced by Th17 cells, which secrete mainly IL-17A and 
IL-17F (Beriou et al., 2010). On the other hand, IL-9 is able 
to induce Th17 cells to differentiate (Elyaman et al., 2009), 
and acts as a mediator of Th17 cell-associated inflammation 
and autoimmune process (Nowak et al., 2009; Singh et al., 
2013). Our previous studies revealed that both Th17 and 
Th9 cells are increased in MPE which is promoted by local 
proinflammatory cytokines, and these Th cells exert an im-
portant immune regulation on lung cancer cells in tumor 
environment (Ye et al., 2010, 2012b). More recently, we 
have demonstrated that IL-17 deficiency promotes angio-
genesis and proliferation activity of pleural tumors as well 
as pleural vascular permeability, and thus promotes MPE 
formation in the animal models of MPE using IL-17/ mice 
(Lin et al., 2014). In the present study, we were prompted to 
explore the impact of IL-17 on the differentiation of Th9 
cells in relation to Th2 cells in a murine model of MPE, and 
to explore whether IL-17 inhibits MPE formation via 
IL-9-dependent mechanism. 
RESULTS 
IL-17 inhibited MPE formation 
In the previous study (Lin et al., 2014), we have demon-
strated that more pleural tumor foci and bloody MPE are 
found in IL-17/ mice as compared with WT mice 14 days 
after intrapleural injection of LLC cells. Here once again we 
confirmed that radiotracer uptake was significantly in-
creased on FDG-PET scanning in IL-17/ mice (Figure 
1A). Furthermore, we found in the current study for the first 
time that the maximum standardized uptake value (SUVmax) 
in WT mice was much lower than that in WT mice injected 
intraperitoneally with anti-IL-17 neutralizing mAb 
(P=0.046); and that SUVmax in IL-17
/ mice injected intra-
peritoneally with rmIL-17 was much lower than that in 
IL-17/ mice (P<0.001) (Figure 1A and B). These data in-
dicate that both endogenous and exogenous IL-17 are capa-
ble of inhibiting the development of MPE. 
As reported in our previous paper (Lin et al., 2014), ex-
pressions of both CD34 and Ki-67 in pleural tumors are 
increased in IL-17/ mice. We extended these work and 
further observed that intraperitoneal injection of anti-IL-17 
mAb in WT mice significantly increased the numbers of 
both CD34+ (Figure 2A) and Ki-67+ cells (P<0.01) (Figure 
2B); while intraperitoneal injection of rmIL­17 in IL-17/ 
mice significantly decreased the numbers of both CD34+ 
and Ki-67+ cells (P<0.01). 
 
Figure 1  Effect of IL-17 on development of malignant pleural effusions 
(MPE). A, Fourteen days after intrapleural injection of Lewis lung cancer 
cells, positron emission tomography and computed tomography imaging of 
developing pleural tumors and MPE in wild type (WT) mice (top panels), 
WT mice receiving intraperitoneal injection of anti-IL­17A mAb 
(WT+anti-IL-17, second panels), IL-17/ mice (third panels), and IL-17/ 
mice receiving intraperitoneal injection of recombinant mouse IL­17A 
(IL-17/+rmIL-17, bottom panels). B, Comparison of maximum standard-
ized uptake value (SUVmax) on positron emission tomography were calcu-
lated among the above four groups (each n=10). Data are presented as 
means±SE. *, P<0.05 compared with WT group; †, P<0.001 compared 
with IL-17/ group, the comparisons were determined by one-way 
ANOVA. 
 
Figure 2  Effect of IL-17 on expression of CD34 and Ki-67 in pleural 
malignant tumor tissues. Tumor tissues were harvested from wild type 
(WT), WT mice receiving intraperitoneal injection of anti-IL­17 mAb 
(WT+anti-IL-17), IL-17/ mice, and IL-17/ mice receiving intraperitoneal 
injection of recombinant mouse IL­17A (IL-17/+rmIL-17), the paraffin 
sections were stained with Abs specific to CD34 and Ki-67, 
4′,6-diamidino-2-phenylindole mounting medium was used for cell nuclei 
staining. Comparisons of CD34+ cells (A) and Ki-67+ cells (B) among the 
above four groups (each n=5) are shown. Data are presented as means±SE. 
*, P<0.01 compared with WT group; †, P<0.01 compared with IL-17/ 
group, the comparisons were determined by one-way ANOVA. 
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Th9 and Th2 cells were significantly increased in MPE 
We next investigated the distribution of Th9 cells in relation 
to Th2 cells in MPE using flow cytometry. In WT mice, a 
significant increase in Th9 cells (Figure 3A and B) and Th2 
cells (Figures 3A and 2C) was observed in MPE, compared 
with those in the corresponding blood and spleen (P<0.01). 
More importantly, we noted that the numbers of Th9 and 
Th2 cells were decreased in MPE from IL-17/ mice as 
compared with those from WT mice (P<0.001). Moreover, 
intraperitoneal injection of anti-IL-17 mAb decreased the 
numbers of MPE Th9 and Th2 cells in WT mice (P<0.001). 
In addition intraperitoneal injection of rmIL-17 increased 
the numbers of MPE Th9 and Th2 cells in IL-17/ mice 
(P<0.001). 
However, the numbers of Th9 and Th2 cells in blood and 
spleen showed no significant differences in either IL-17/ 
or WT mice (P>0.05). 
Expressions of IL-9, IL-4, IRF4, and GATA-3 mRNA in 
MPE 
The mRNA expression of IL-9 (Figure 4A) and IL-4 (Fig-
ure 4B) was much lower in MPE from IL-17/ mice than 
those from WT mice (P<0.01). The intraperitoneal injection 
of anti-IL-17 mAb in WT mice significantly decreased  
mRNA expression of IL-9 and IL-4, whereas the intraperi-
toneal injection of rmIL­17 in IL-17/ mice significantly 
increased mRNA expression of IL-9 and IL-4 (P<0.01). In 
parallel to the change in mRNA expression of IL-9 and 
IL-4, very similar change patterns in mRNA expression of 
IRF4 (Figure 4C) and GATA-3 (Figure 4D) were also ob-
served (P<0.01). 
IL-17 affects survival of mice bearing MPE via 
IL-9-dependent mechanism 
The median survival times of WT, WT+anti-IL-9, IL-17/, 
and IL-17/+rmIL-9 mice bearing MPE were 26.0, 19.0, 
20.0, and 26.0 days, respectively. The overall log rank test 
for survival among these four groups was significant 
(P<0.001). Pair-wise log rank tests showed that the survival 
of IL-17/ mice was much shorter than that of WT mice 
(P<0.001). Intraperitoneal injection of anti-IL-9 mAb ac-
celerated the death of WT mice (P<0.001), whereas intra-
peritoneal injection of rmIL-9 improved the survival of 
IL-17/ mice (P<0.001) (Figure 5). The survival of the two 
control groups (isotype mAb control for WT+anti-IL-9 
group and PBS containing 0.1% albumin control for 
IL-17/+rmIL-9 group) was similar to that of WT mice 
(data not shown). 
 
 
Figure 3  Effect of IL-17 on distributions of Th9 and Th2 cells in malignant pleural effusions (MPE), blood and spleen. A, The representative flow cy-
tometric dot plots of Th9 and Th2 cells in wild type (WT) mice (top panels), WT mice receiving intraperitoneal injection of anti-IL­17 mAb (WT+anti-IL-17, 
second panels), IL-17/ mice (third panels), and IL-17/ mice receiving intraperitoneal injection of recombinant mouse IL­17 (IL-17/+rmIL-17, bottom 
panels). Comparisons of percentages of Th9 (B) and Th2 cells (C) in MPE, blood and spleen from the above four groups (each n=10). Data are presented as 
means±SE. *, P<0.01 compared with blood and spleen, the comparisons were determined by two-way ANOVA. †, P<0.001 compared WT mice; ‡, P<0.001 
compared with IL-17/ mice, the comparisons were determined by one-way ANOVA. 
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Figure 4  mRNA expression of IL-9 and IL-4 and their corresponding transcription factors in malignant pleural effusions (MPE). The mononuclear cells 
were isolated from MPE of wild type (WT) mice (top panels), WT mice receiving intraperitoneal injection of anti-IL­17 mAb (WT+anti-IL-17, second pan-
els), IL-17/ mice (third panels), and IL-17/ mice receiving intraperitoneal injection of recombinant mouse IL­17 (IL-17/+rmIL-17, bottom panels). RNA 
was isolated, and qPCR was performed for il9 mRNA (A), il4 mRNA (B), irf4 mRNA (C), and gata3 mRNA (D). Electrophoresis’ photographs are representa-
tives of four independent experiments. Data are presented as mean±SE of four experiments. *, P<0.01 compared with WT mice; †, P<0.01 compared with 
IL-17/ mice, the comparisons were determined by one-way ANOVA. 
DISCUSSION 
In the presence of TGF-1, IL-9 differentiates naïve CD4+ 
T cells into Th17 cells; IL-9 also enhances the suppressive 
functions of Tregs in vitro. The mechanism by which IL-9 
affects Th17 cells and Tregs is through activation of STAT3 
and STAT5 signaling (Elyaman et al., 2009). Singh and 
colleagues have shown that IL-9 has a role in the develop-
ment of psoriatic lesions through Th17 cell-associated in-
flammation and angiogenesis (Singh et al., 2013). Zhou and 
colleagues have reported hat IL-9 induces chemokine 
CCL-20 production by astrocytes to enhance the infiltration 
of Th17 cells into the central nervous system (Zhou et al., 
2011). To the best of our knowledge, the current study was 
the first one to explore the impact of IL-17 on the differen-
tiation and immune regulation of Th9 cells. 
The contribution of IL-17 or Th17 cells to tumor immun-
ity has been well documented (Ye et al., 2013; Zou and 
Restifo, 2010). Our previous studies showed that Th17 cell 
numbers in MPE are significantly increased, and that 
overrepresentation of Th17 cells in MPE may be due to 
Th17 cell differentiation and expansion stimulated by local 
proinflammatory cytokines, and to recruitment of Th17 cells 
from blood induced by pleural chemokines CCL20 and  
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Figure 5  IL-17 improved survival of mice bearing malignant pleural 
effusion by affecting Th9 response. Mice (15 mice per group) were admin-
istered intrapleural injection of Lewis lung cancer cells. Life span analysis 
showed that IL-17/ group had a significant shorter survival than wild type 
(WT) group; intraperitoneal injection of WT mice with anti-IL-9 mAb 
(WT+anti-IL-9) had a significant shorter survival than WT group; and 
intraperitoneal injection of recombinant mouse IL-9 (IL-17/+IL-9) had a 
significant improved survival compared with IL-17/ mice. Overall surviv-
al was estimated by the Kaplan-Meier method and compared by the 
log-rank test. 
CCL22 (Ye et al., 2010). On the other hand, Tregs inhibit 
the generation and differentiation of Th17 cells via a laten-
cy-associated peptide-dependent mechanism (Ye et al., 
2011). More recently, we have demonstrated that IL-17 de-
ficiency promotes angiogenesis and proliferation activity of 
pleural tumors as well as pleural vascular permeability, and 
thus promotes MPE formation (Lin et al., 2014). The find-
ing that IL-17 deficiency accelerates the death of mice 
bearing MPE observed in the animal study (Lin et al., 2014) 
is consistent with the finding that the accumulation of Th17 
cells in MPE predicts improved patient survival in the hu-
man study (Ye et al., 2010). Consistent with our previous 
findings (Lin et al., 2014), we confirmed that IL-17 defi-
ciency promoted MPE formation by enhancing the angio-
genesis and proliferation of pleural tumors, and that in vivo 
administration of anti-IL-17 mAb in WT mice was able to 
promote MPE formation by increasing tumor angiogenesis 
and proliferation, while in vivo administration of rmIL-17 in 
IL-17/ mice was able to inhibit MPE formation by dimin-
ishing tumor angiogenesis and proliferation. 
Previous studies have suggested that IL-9 plays an im-
portant role in NK/T-cell lymphoma possibly via an auto-
crine mechanism (Nagato et al., 2005). Purwar and col-
leagues (Purwar et al., 2012) have demonstrated that that 
mice deficient in Th17 cell development have substantial 
resistance to melanoma growth in a IL-9-dependent manner; 
and treatment with exogenous IL-9 inhibits tumor growth in 
vivo. Lu and colleagues have found that tumor-infiltrating 
Th9 cells induce lung tumor tissues, especially epithelial 
cells, to express CCL20, which recruits inflammatory cells, 
especially dendritic cells, into tumor sites, and subsequently 
promotes a strong activation response of CD8+ tu-
mor-infiltrating lymphocytes (Lu et al., 2012). These data 
suggest a distinct role for tumor-specific Th9 cells in pro-
voking CD8+ T cell-mediated anti-tumor immunity. On the 
other hand, intratumor Th2 cells have been shown to corre-
late with cancer-associated fibroblast thymic stromal lym-
phopoietin production and to reduce survival of cancer pa-
tients (De Monte et al., 2011). The relationship between 
Th9 cells and Th2 cells is of particular interest, and their 
immune regulation is often linked to proinflammatory pro-
cesses and tumor immunity. We therefore explored the dis-
tribution of Th9 cells in relation to Th2 cells in MPE and 
found that the numbers of both Th9 and Th2 cells in MPE 
were significantly higher than those in blood and 
spleen.Nevertheless the numbers of Th9 and Th2 cells were 
significantly lower in MPE, but not in either spleen or 
blood, from IL-17/ mice than those from WT mice, indi-
cating that the differentiation of Th9 and Th2 cells in MPE 
can be promoted by IL-17 in vivo. 
Since IRF4 is a transcription factor that is essential for 
the developmental program of Th9 cells (Staudt et al., 2010; 
Tamiya et al., 2013), and the differentiation of Th2 cell lin-
eage requires the upregulation of  GATA-3 (Zheng and 
Flavell, 1997; Zhou and Ouyang, 2003), we thus examined 
mRNA expression of IL-9 and IL-4 simultaneously with 
mRNA expression of IRF4 and GATA-3, and found that 
there was much lower mRNA expression of IL-9 and IRF4 
in MPE from IL-17/ mice than that from WT mice. Simi-
larly, mRNA expression of IL-4 and GATA-3 was also 
lower in MPE from IL-17/ mice than that from WT mice. 
Collectively, our data suggested that IL-17 enhances differ-
entiation Th9 and Th2 cells by up-regulating expression of 
IRF4 and GATA-3, respectively. 
Our previous data showed that IL-9 significantly pro-
motes the proliferation response and migratory activity of 
lung cancer cells by activating STAT3 signaling, and that 
IL-9 strongly promotes intercellular adhesion of lung cancer 
cells to pleural mesothelial cells by upregulating the expres-
sion of cellular adhesion molecules ICAM-1, LFA-1 and 
VCAM-1 on both cancer cells and pleural mesothelial cells 
(Ye et al., 2012b). All these functional aspects of IL-9 pro-
vide the explanation for our observation that the accumula-
tion of Th9 cells in MPE predicts reduced patient survival, 
with increased risk for death in MPE patients (Ye et al., 
2012b). In the present study, we noted a significant correla-
tion between IL-17 deficiency and mouse survival. The ab-
sence of IL-17 was a significant predictor for short survival 
of MPE mice, intraperitoneal injection of anti-IL-9 neutral-
izing mAb accelerated the death of WT mice bearing MPE, 
and intraperitoneal injection of rmIL-9 improved the sur-
vival of IL-17/ mice bearing MPE. Our data indicate that 
IL-17 reduces the death of mice bearing MPE via 
IL-9-dependent mechanism. 
In conclusion, we have demonstrated that both Th9 and 
Th2 cells were decreased in MPE from IL-17/ mice as 
compared with WT mice. IL-17 inhibits MPE formation by 
attenuating angiogenesis and proliferation of pleural tumor, 
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and thus reduces the death of mice bearing MPE via 
IL-9-dependent mechanism. Thus, therapeutic intervention 
aiming at interfering Th17 or/and Th9 cells may be benefi-
cial for improving prognosis in patients with MPE. 
MATERIALS AND METHODS 
Animals 
Wild type (WT) C57BL/6 mice were purchased from the 
Animal Center of Wuhan University (Wuhan, China). 
IL-17a/ mice in a C57BL/6 background were generated as 
previously described (Nakae et al., 2002) and were provided 
by Dr. Iwakura (University of Tokyo, Japan). Mice used for 
experiments were sex-, weight (20–25 g)-, and age (8–12 
wk)-matched. The mice were maintained on a chow diet in 
a 12-hour light/12-hour dark environment at 25°C in Ani-
mal Care Facility of Beijing Chaoyang Hospital or in Tongji 
Medical College Animal Care Facility, according to institu-
tional guidelines. All animal studies were approved by In-
stitutional Animal Care and Utilization Committees of Bei-
jing Chaoyang Hospital, Capital Medical University and 
Tongji Medical College, Huazhong University of Science 
and Technology. 
MPE Model 
A mouse model of MPE by intrapleural injecting Lewis 
lung cancer (LLC) cells was made as described previously 
(Lin et al., 2014). Briefly, mice were anesthetized by 
isoflurane inhalation, the skin overlying the anterior and 
lateral chest wall was shaved and disinfected, and a 
5-mm-long trans-verse skin incision was made on the right 
anterolateral thoracic area at the xiphoid level. Fascia and 
muscle were retracted, and 1.5×105 LLC cells (purchased 
from the American Type Culture Collection (Manassas, 
USA) suspended in 50 μL phosphate buffered saline (PBS) 
were injected into pleural cavity through an intercostal 
space under direct observation. The skin incision was closed 
using continuous 5-0 Ethilon monofilament suture, and the 
animals were monitored until complete recovery. 
Sample collection and processing 
Fourteen days after pleural injection of LLC cells, mice 
were euthanized by CO2 asphyxiation, and blood was drawn 
from the retro-orbital veins. Thereafter, the abdominal wall 
was opened, and the viscera were retracted to visualize the 
diaphragm. Pleural fluid was gently aspirated using a 3-mL 
syringe, and its volume was measured with a 1,000-μL pi-
pette. Smear slides were made from samples for Wright- 
Giemsa staining and were determined for leukocyte differ-
ential counts under light microscope. 
MPE and blood samples from each mouse were collected 
in heparin-treated tubes, and were immersed in ice immedi-
ately and were then centrifuged at 300×g for 10 min. In 
order to obtain spleen cell suspension, spleens were re-
moved and cut into small pieces, and then minced in PBS 
and filtered. The cell pellets of MPE, blood, and spleen 
were resuspended in PBS, and mononuclear cells were iso-
lated by Ficoll-Hypaque gradient centrifugation (Pharmacia, 
Sweden) to determine T cell subsets within 1 h. 
In vivo treatment of mice 
At days 1, 3, 6, 9, and 12 after intrapleural instillation of 
LLC cells, WT mice (n=10) received intraperitoneal injec-
tion of 100 µg anti-IL­17A neutralizing mAb (clone 
eBioMM17F3, eBioscience, lgG1, USA) or 100 µg mouse 
IgG1 isotype control mAb (eBioscience); while IL-17/ 
mice were injected intraperitoneally at a dose of 1 μg re-
combinant mouse (rm) IL­17A diluted in PBS containing 
0.1% albumin (R&D System, USA) or PBS containing 
0.1% albumin in a total volume of 100 μL. The administra-
tion regimens of anti-IL-17 mAb and rmIL-17 were based 
upon our preliminary experiments. 
Positron emission tomography (PET) and computed 
tomography (CT) scanning 
All PET images were acquired using Trans-PET® BioCali-
burnTM LH (Raycan Technology Co., Ltd, Suzhou) consist-
ing of 12 basic detector modules. Fifteen-min PET scans 
were begun between 60 and 70 min after retro-orbital injec-
tion of 200–300 μCi of 18-fluoro-6-deoxy-glucose. In con-
sideration of the PET system’s spatial resolution, recon-
structed PET images had pixel dimensions of (0.5 mm)2 and 
0.5 mm slice thickness. Furthermore, due to the OSEM re-
construction method using point spread function system 
response matrix, the size of the reconstructed 3D image was 
set to be 280×280×104 (X×Y×Z) that must be smaller than 
or equal to the size of point spread function system response 
matrix. Also, CT images were acquired on a small animal 
CT scanner provided by the Trans-PET system with char-
acteristics of an axial field of view of 5.0 cm, a radial field 
of view of 7.0 cm and a spatial resolution of 0.5 mm. The 
PET and CT images were acquired with the mouse under 
anesthesia in a common animal holder. The co-registration 
of the images was implemented using the AMIDE software 
package (The Free Software Foundation Inc., USA). 
Immunofluorescence staining 
Pleural tumor tissues were fixed in 4% paraformaldehyde, 
embedded with paraffin. The paraffin-embedded tissues 
were cut into 5-µm thick sections that were mounted on 
glass slides. The primary Abs were rat anti-mouse CD34 
mAb (both were purchased from Abcam, UK) and rabbit 
mAb targeted against mouse Ki-67, appropriate spe-
cies-matched Abs were used as isotype controls. As sec-
ondary Abs, dylight 488-conjugated affinity-purified goat 
anti-rat IgG (EarthOx, USA) was used for labeling the rat 
anti-mouse CD34 mAb, and cy3-conjugated affini-
ty-purified goat anti-rabbit IgG (Proteintech Group Inc, 
USA) was used for labeling the rabbit anti-mouse Ki-67 Ab. 
The slides were processed and then incubated with 10% 
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goat serum in PBS at room temperature for 30 min, and then 
incubated at 4°C overnight with 1/500 concentrations of 
primary Abs. After washing, slides were incubated with 
secondary Abs for 120 min at room temperature in the dark. 
4′,6-diamidino-2-phenylindole mounting medium (Vector 
Laboratories, USA) was used for cell nuclei staining. Final-
ly, slides were examined under laser scanning confocal mi-
croscope (Olympus FV500; Olympus, Japan). 
Flow cytometry 
For intracellular detection of cytokines, cells were stimu-
lated for 4 h at 37°C with 50 ng mL1 PMA (Sigma-Aldrich, 
USA) and 1 μg mL1 ionomycin (Sigma-Aldrich) in the 
presence of Brefeldin A (10 µg mL1, Enzo Life Science, 
USA). The Abs including anti-CD3, -CD8, -IL-4, 
-GATA-3, and -interferon-regulatory factor 4 (IRF4) mAbs 
were purchased from BDPharmingen (San Diego, USA) or 
eBioscience (San Diego). Cells were surface-stained with 
anti-CD3 and -CD8 mAbs in PBS+2% heat-inactivated fetal 
bovine serum (FBS, Gibco, USA) for 20 min at 4°C. Cells 
were resuspended in a fixation/permeabilization solution 
(Cytofix/Cytoperm; BD Pharmingen, USA) and incubated 
with anti-IL-4, -IL-9, -GATA-3 or -IRF4 mAbs for 30 min 
at 4°C. Cells were then washed with permeabilization buffer 
and resuspended in PBS+2% FBS for flow cytometric anal-
ysis (FACSCanto II; BD Bioscience, USA). Flow cytometry 
was performed on a FACS Canto II (BD Biosciences) and 
analyzed using BD FCSDiva Software and FCS Express 4 
software (De Novo Software, USA). 
Quantitative real time PCR 
Total RNA was isolated from cell pellets with Trizol rea-
gent (Invitrogen, USA). cDNAs were synthesized with oli-
go (dT) primers using the First Strand cDNA Synthesis Kit 
ReverTra Ace--(TOYOBO, Japan). cDNAs were used as 
templates in real time PCR with the SYBR Green I Real 
time PCR Master Mix (TOYOBO). DNA was amplified 
under the following typical cycling conditions: denaturation 
at 95°C for 15 s, annealing at 58°C for 20 s, extension at 
72°C for 20 s. The samples were amplified for 40 cycles. 
The following primers were used: for il4, forward primer: 
5′-TGTCATCCTGCTCTTCTTTCTC-3′, reverse primer: 
5′-CACTCTCTGTGGTGTTCTTCGT-3′; for il9, forward 
primer: 5′-GGTGACATACATCCTTGCCTCT-3′, reverse 
primer: 5′-CCCTCCCTGTAGCACGGT-3′; for gata3, for-
ward primer: 5′-TTACCACCTATCCGCCCTA-3′ reverse 
primer: 5′-ACACTCCCTGCCTTCTGTG-3′; for irf4, for-
ward primer: 5′-CAATGTCCTGTGACGTTTGG-3′, re-
verse primer: 5′-GGCTTCAGCAGACCTTATGC-3′; for 
-actin, forward primer: 5′-CTGAGAGGGAAATCGTG- 
CGT-3′, reverse primer: 5′-CCACAGGATTCCATACCC- 
AAGA-3′. -actin was used as an internal control, and lev-
els of each gene were normalized to -actin expression us-
ing the ∆∆Ct-method, with WT mouse experimental value 
set to 1. PCR products were also analyzed in 2% agarose gel 
electrophoresis. 
Survival advantage 
The observation of survival advantage included 3 groups of 
WT and 3 groups of IL-17/ mice (each n=15). At days 1, 
3, 6, 9, and 12 after intrapleural instillation of LLC cells, 2 
groups of WT mice received intraperitoneal injection of 100 
µg anti-IL-9 neutralizing mAb (clone D9302C12, eBiosci-
ence) (WT+anti-IL-9) or 100 µg mouse isotype control mAb 
(eBioscience), respectively; and 2 groups of IL-17/ mice 
received intraperitoneal injection of 1 μg rmIL-9 (R&D- 
System, USA) diluted in PBS containing 0.1% albumin 
(IL-17/+rmIL-9) or PBS containing 0.1% albumin in a 
total volume of 200 μL, respectively. One group of WT and 
1 group of IL-17/ mice receiving no intraperitoneal injec-
tions served as controls. The mice without heartbeat and 
breathing were determined to be dead. The doses of an-
ti-IL-9 mAb and rmIL-9 were based upon our preliminary 
experiments. 
Statistics 
Data were normally distributed, and all values are expressed 
as mean±SE. Differences between two or multiple experi-
mental groups were compared using Student’s t test, 
one-way analysis of variance (ANOVA), or two-way 
ANOVA, as appropriate. Survival was estimated by the 
Kaplan-Meier method and compared by the log-rank test. 
Analysis was completed with SPSS version 16.0 Statistical 
Software (USA), and P<0.05 was considered to indicate 
statistical significance. 
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